```html

Gamma‑hydroxybutyrate (GHB) Poisoning – A Comprehensive Guide

Overview

Gamma‑hydroxybutyrate (GHB) is a central‑acting depressant that occurs naturally in the brain in small amounts. In the United States and many other countries it is also manufactured for medical use (e.g., sodium oxybate for narcolepsy) and, illegally, as a recreational “party drug” or “date‑rape” substance.

When taken in doses higher than therapeutic levels, GHB can cause rapid onset of intoxication and, in severe cases, life‑threatening respiratory depression and coma—referred to as GHB poisoning. The condition is a medical emergency because the therapeutic window is narrow: the difference between a euphoric dose (≈1–2 g) and a toxic dose (≥5 g) can be small.

Who is affected? Young adults (18‑35 y) who attend nightclubs, raves, or private parties are the most common demographic for recreational misuse. However, poisoning can also occur inadvertently when people take “liquid ecstasy” (often sold as “G” or “GBL”) or combine GHB with alcohol or other depressants.

Prevalence. According to the 2022 National Survey on Drug Use and Health (NSDUH), approximately 500,000 Americans reported using GHB in the past year, with about 30,000 emergency department (ED) visits attributed to GHB intoxication or overdose annually in the U.S. Worldwide, the exact incidence is harder to track, but the European Monitoring Centre for Drugs and Drug‑Addiction (EMCDDA) estimates a rising trend in GHB‑related harms across Europe, particularly among club‑going populations.

Symptoms

The clinical presentation of GHB poisoning is dose‑dependent and can evolve quickly (within 15‑30 minutes after ingestion). Symptoms are grouped into three stages: early, moderate, and severe.

Early (1–2 g)

• Euphoria and disinhibition – feelings of warmth, sociability.
• Drowsiness – heavy eyelids, desire to nap.
• Vertigo or disequilibrium – “the room feels like it’s moving.”
• Mild nausea – often followed by vomiting if the dose escalates.
• Flushing – pinkish skin, especially on the face and neck.

Moderate (2–5 g)

• Impaired coordination – ataxia, stumbling, slurred speech.
• Confusion / delirium – inability to follow commands, disorientation to time/place.
• Bradycardia – heart rate < 60 bpm.
• Hypotension – systolic BP < 90 mm Hg.
• Respiratory depression – shallow, irregular breathing (RR < 12/min).
• Vomiting with risk of aspiration.

Severe (>5 g or combination with alcohol/benzodiazepines)

• Coma or unresponsiveness – no response to painful stimuli.
• Severe respiratory arrest – may require bag‑valve‑mask ventilation or intubation.
• Marked bradycardia or arrhythmias.
• Hypoglycemia – blood glucose < 70 mg/dL.
• Seizures – less common but reported, especially with co‑intoxicants.
• Cardiac arrest – rare but possible in massive overdoses.

Symptoms often fluctuate because GHB has a short half‑life (≈30–60 minutes). Patients may appear to recover and then deteriorate again, a phenomenon known as “re‑emergence” after the initial “bounce‑back” effect.

Causes and Risk Factors

GHB poisoning results from the ingestion of excessive amounts of GHB or its pro‑drugs (γ‑butyrolactone – GBL, 1,4‑butanediol – 1,4‑BD). The following factors increase risk:

• Recreational misuse – especially in party settings where dose‑tracking is unreliable.
• Polydrug use – co‑consumption of alcohol, benzodiazepines, opioids, or stimulants amplifies central nervous system depression.
• Poor body weight or low tolerance – women and individuals with low body mass experience toxicity at lower absolute doses.
• Unintentional ingestion – GHB marketed as “liquid ecstasy” or “research chemicals” can be mistaken for other drinks.
• Medical misuse – patients prescribed sodium oxybate for narcolepsy who exceed prescribed amounts.
• Chronic use – tolerance can lead users to increase dose, raising overdose risk.

Diagnosis

Because GHB is rapidly metabolized, diagnosis relies heavily on clinical suspicion and history rather than laboratory confirmation.

Clinical Assessment

• Focused history – recent party attendance, known ingestion of “G”, “GBL”, “liquid ecstasy”, or prescription sodium oxybate.
• Physical exam – assess airway, breathing, circulation, pupil size (usually normal or slightly constricted), level of consciousness.
• Vital signs – monitor for bradycardia, hypotension, hypoxia.

Laboratory & Toxicology Tests

• Blood GHB level – specialized gas chromatography–mass spectrometry (GC‑MS); not routinely available in most EDs and must be ordered within 6 hours of exposure.
• Serum ethanol and other drug screens – to rule out concurrent intoxication.
• Basic metabolic panel – check glucose, electrolytes, renal function.
• Arterial blood gas (ABG) – assess for respiratory acidosis.

Imaging

Usually not required unless trauma or other complications are suspected. A chest X‑ray may be performed if aspiration is a concern.

Diagnostic Criteria (CDC/Clinical Toxicology)

Diagnosis is made when all of the following are present:

1. History of possible GHB exposure within the past 12 hours.
2. Rapid onset (≤30 min) of central nervous system depression.
3. Absence of an alternative explanation (e.g., stroke, infection).
4. Improvement after supportive care (or documented GHB level if available).

Treatment Options

There is no specific antidote for GHB. Management is primarily supportive, focusing on airway protection, breathing support, and circulatory stability.

Emergency Stabilization

• Airway – Position the patient, suction oral secretions, and consider endotracheal intubation for GCS ≤ 8 or worsening respiratory depression.
• Breathing – Administer supplemental O₂; if hypoventilation persists, use bag‑valve‑mask ventilation or mechanical ventilation.
• Circulation – IV access, isotonic fluids (normal saline) for hypotension; avoid excessive fluids if cardiac dysfunction is suspected.
• Monitoring – Continuous cardiac monitoring, pulse oximetry, and capnography.

Pharmacologic Interventions

• Flumazenil – NOT recommended; GHB is not a benzodiazepine and flumazenil may precipitate seizures.
• Diazepam or lorazepam – Can be used for seizure control if it occurs.
• Glucose – Administer 50 mL of 50 % dextrose IV if hypoglycemia is present.
• Activated charcoal – May be considered if the patient presents within 1 hour of ingestion and has a protected airway; evidence of benefit is limited.

Observation Period

Because GHB’s effects can re‑emerge after the initial “bounce‑back,” patients should be observed for at least 4–6 hours after symptom resolution. In cases of co‑intoxicants, longer monitoring may be required.

Discharge Planning

• Ensure the patient (or a responsible adult) understands the risks of future use.
• Provide written information about treatment resources (substance‑use counseling, hotlines).
• Arrange follow‑up within 24‑48 hours for at‑risk individuals.

Living with Gamma‑hydroxybutyrate (GHB) Poisoning

For individuals who have experienced an overdose, long‑term health is usually good if the acute event is survived. Ongoing management focuses on preventing recurrence and addressing any underlying substance‑use disorder.

Key Lifestyle Strategies

• Avoid all non‑prescribed GHB, GBL, and 1,4‑BD. Even small amounts can trigger relapse.
• Limit alcohol and other depressants – they potentiate GHB’s effects.
• Engage in counseling or therapy – Cognitive‑behavioral therapy (CBT) and motivational interviewing have shown efficacy in reducing stimulant and depressant misuse (NIH, 2023).
• Consider medication‑assisted treatment (MAT) if polysubstance dependence is present (e.g., buprenorphine for opioid co‑use).
• Carry emergency information – Medical ID bracelet noting “GHB overdose risk” can aid first responders.
• Stay hydrated and maintain regular meals – low blood sugar can worsen confusion.

Follow‑up Care

Schedule appointments with:

• Primary care physician – to monitor liver/kidney function and screen for mood disorders.
• Addiction specialist – for ongoing support and possible enrollment in a recovery program.
• Psychiatrist – if depression, anxiety, or psychosis emerge after the overdose.

Prevention

Preventing GHB poisoning requires both individual and community‑level actions.

Individual Measures

• Know the substance – Recognize that “G”, “liquid ecstasy”, “GBL”, and “research chemicals” may contain GHB.
• Never mix GHB with alcohol or benzodiazepines – the combination is synergistically dangerous.
• Use a trusted source for prescription sodium oxybate – keep it in a child‑proof container and take only the prescribed dose.
• Carry a drug‑testing kit – reagent strips can detect GHB/GBL in drinks (available online).

Community & Policy Strategies

• Increase public‑health campaigns targeting college campuses about the risks of GHB.
• Strengthen law‑enforcement controls on the sale of GBL and 1,4‑BD, which are precursors.
• Implement training for bar and club staff to recognize signs of GHB intoxication.
• Encourage EDs to develop protocols for rapid assessment and observation of suspected GHB cases.

Complications

If not identified and treated promptly, GHB poisoning can lead to:

• Respiratory failure – may cause hypoxic brain injury.
• Aspiration pneumonia – due to vomiting while unconscious.
• Cardiac arrhythmias – especially in the setting of hypoxia or electrolyte disturbances.
• Seizure‑related injury – falls or trauma during a seizure.
• Long‑term neurocognitive deficits – rare, but reported after prolonged hypoxia.
• Death – Estimated fatality rate for severe GHB overdose is <1 % when rapid medical care is provided, but rises to 4–6 % with co‑intoxicants (CDC, 2022).

When to Seek Emergency Care

---

Sources: Mayo Clinic, CDC, National Institute on Drug Abuse (NIDA), European Monitoring Centre for Drugs and Drug‑Addiction (EMCDDA), NIH, WHO, Cleveland Clinic, peer‑reviewed toxicology journals (2021‑2024).

```